{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=chlorambucil", "query": { "intervention": "chlorambucil" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 21, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=chlorambucil&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T07:59:59.961Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00046683", "title": "Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Cell Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 284, "start_date": "2001-07", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2016-07-28", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 20, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Fort Myers, Florida + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Hines", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046683" }, { "nct_id": "NCT02612311", "title": "Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Obinutuzumab", "type": "BIOLOGICAL" }, { "name": "Ublituximab", "type": "BIOLOGICAL" }, { "name": "TGR-1202", "type": "DRUG" }, { "name": "Chlorambucil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 603, "start_date": "2015-11-19", "completion_date": "2023-02-22", "has_results": true, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 110, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 100 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02612311" }, { "nct_id": "NCT02788201", "title": "Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer", "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "75 approved agents", "type": "DRUG" }, { "name": "COXEN", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2017-03-27", "completion_date": "2019-10-23", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788201" }, { "nct_id": "NCT01724346", "title": "Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Next-line ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 269, "start_date": "2013-12-03", "completion_date": "2023-08-18", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 16, "location_summary": "Duarte, California • La Jolla, California • Stanford, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01724346" }, { "nct_id": "NCT01980875", "title": "Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Chlorambucil", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2015-04-21", "completion_date": "2016-05-13", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 6, "location_summary": "Santa Barbara, California • Santa Monica, California • Whittier, California + 3 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01980875" }, { "nct_id": "NCT01088048", "title": "Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Indolent Non-Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Chlorambucil", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 241, "start_date": "2010-03-25", "completion_date": "2015-04-28", "has_results": true, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 11, "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088048" }, { "nct_id": "NCT00117598", "title": "Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Temsirolimus (CCI-779)", "type": "DRUG" }, { "name": "Investigator's choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2005-05", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2015-03-30", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 19, "location_summary": "Little Rock, Arkansas • Fountain Valley, California • Los Angeles, California + 16 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Milford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117598" }, { "nct_id": "NCT01998880", "title": "CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphocytic Leukemia, Chronic" ], "interventions": [ { "name": "obinutuzumab", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "chlorambucil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 787, "start_date": "2009-12-22", "completion_date": "2017-08-23", "has_results": true, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 5, "location_summary": "San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Green Bay", "state": "Wisconsin" }, { "city": "Waukesha", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998880" }, { "nct_id": "NCT00910910", "title": "Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B-Cell Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Chlorambucil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 450, "start_date": "2009-10-13", "completion_date": "2018-05-09", "has_results": true, "last_update_posted_date": "2019-07-09", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 28, "location_summary": "Escondido, California • Whittier, California • New Britain, Connecticut + 25 more", "locations": [ { "city": "Escondido", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Centralia", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00910910" }, { "nct_id": "NCT00748189", "title": "Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukaemia, Lymphocytic, Chronic" ], "interventions": [ { "name": "chlorambucil, tablets", "type": "DRUG" }, { "name": "ofatumumab (GSK1841157) infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2008-12-22", "completion_date": "2018-05-17", "has_results": true, "last_update_posted_date": "2019-06-25", "last_synced_at": "2026-09-03T07:59:59.961Z", "location_count": 30, "location_summary": "Sedona, Arizona • Tucson, Arizona • Murrieta, California + 25 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Murrieta", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00748189" } ] }